Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Issued (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Shares Issued data on record, last reported at $107000.0 in Q3 2025.

  • For Q3 2025, Shares Issued rose 723.08% year-over-year to $107000.0; the TTM value through Dec 2025 reached $107000.0, down 86.25%, while the annual FY2025 figure was $107000.0, 86.25% down from the prior year.
  • Shares Issued reached $107000.0 in Q3 2025 per CCCC's latest filing, down from $111000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $873000.0 in Q3 2021 and bottomed at -$730000.0 in Q4 2022.
  • Average Shares Issued over 5 years is $218200.0, with a median of $166000.0 recorded in 2021.
  • Peak YoY movement for Shares Issued: tumbled 197.07% in 2022, then skyrocketed 6650.0% in 2024.
  • A 5-year view of Shares Issued shows it stood at $752000.0 in 2021, then crashed by 197.07% to -$730000.0 in 2022, then skyrocketed by 100.27% to $2000.0 in 2023, then surged by 5450.0% to $111000.0 in 2024, then dropped by 3.6% to $107000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $107000.0 in Q3 2025, $111000.0 in Q4 2024, and $13000.0 in Q3 2024.